Raymond James lowers Revvity stock price target to $115 on China headwinds

Published 29/07/2025, 17:38
Raymond James lowers Revvity stock price target to $115 on China headwinds

Investing.com - Raymond (NSE:RYMD) James lowered its price target on Revvity Inc (NYSE:RVTY) to $115.00 from $120.00 on Tuesday, while maintaining an Outperform rating following the company’s second-quarter earnings report. The company, currently trading at $95.71, maintains strong financial health with a perfect Piotroski Score of 9, according to InvestingPro data.

The firm cited reimbursement headwinds in China as the primary reason for the adjustment, specifically pointing to a change in coverage for multiplex immunodiagnostics that will impact Revvity’s growth for the remainder of the year.

Revvity has reduced its organic growth forecast to 2-4%, representing a 100 basis point cut from previous guidance, directly attributable to the Chinese reimbursement changes.

Despite these challenges, Raymond James noted that Revvity’s remaining business performed as expected, with margin reductions explained by the diagnostic-related group changes and foreign exchange impacts, which management expects to fully offset by 2026.

The stock fell approximately 8% in response to the news, though Raymond James continues to project approximately 6% organic growth in future years with expanding margins that the firm believes are currently undervalued by the market.

In other recent news, Revvity Inc. reported its second-quarter 2025 earnings, which exceeded analyst expectations. The company announced an adjusted earnings per share of $1.18, surpassing the forecasted $1.14, and revenue of $720 million, beating the anticipated $710.39 million. Despite these positive results, the company faces challenges related to China’s drug-related group policies, which have influenced its financial outlook. As a result, Jefferies has lowered its price target for Revvity to $100 from $106, while maintaining a Hold rating. Similarly, Bernstein SocGen Group reduced its price target to $115 from $120, retaining a Market Perform rating. Both firms cite concerns over China-related headwinds as reasons for their adjustments. These developments highlight the mixed reactions from analysts despite Revvity’s strong quarterly performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.